tirzepatide weight loss edgewater Downtown Medspa - NJ Tirzepatide – Medical Weight Loss

More possible momentum for tirzepatide The data could drive more momentum for tirzepatide, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) dual agonist that generated $1.55 billion in sales in the first half of 2023

It may also worsen existing GERD or trigger reflux symptoms in people who are already prone to it

To learn more, visit Media Contact Company Name: Medvi Contact Person: Support Email: Send Email Country: United States Website: en-medvi.com Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Medvi Expands Doctor-Led GLP-1 Weight Management Services Through Its Telehealth Platform This article contains syndicated content

The STEP trials (published 2021-2022) enrolled over 4,500 participants